Cohance Lifesciences Stock Hits 52-Week Low at Rs. 615.1

Cohance Lifesciences has reached a significant milestone by hitting a new 52-week low of Rs. 615.1 on November 14, 2025. This decline marks a notable downturn for the small-cap pharmaceutical and biotechnology company, which has been underperforming in the market. Over the past 12 days, the stock has experienced a consecutive fall, resulting in a total decline of 27.08%. Today's performance saw the stock underperforming its sector by 1.41%, with an intraday low of Rs. 615.1, reflecting a decrease of 2.29%. In terms of moving averages, Cohance Lifesciences is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent downward trend. In the broader market context, the Sensex opened lower and is currently trading at 84,318.06, down 0.19%. Despite the overall market conditions, small-cap stocks are showing some resilience, with the BSE Small Cap index gaining 0.2%. However, Cohance Lifesciences' one-year performance stands at a stark -51.31%, contrasting sharply with the Sensex's positive return of 8.66%.